Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Key Information About Hims & Hers Health – A Stock Analysis

Shares of Health Care sector company Hims & Hers Health moved -3.7% today, and are now trading at a price of $42.5. The Mid-Cap stock's daily volume was 11,052,822 compared to its average volume of 38,557,731. The S&P 500 index returned a -1.0% performance.

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company is based in San Francisco and has 1,637 full time employees. Its market capitalization is $9,606,460,416.

11 analysts are following Hims & Hers Health and have set target prices ranging from $28.0 to $85.0 per share. On average, they have given the company a rating of hold. At today's prices, HIMS is trading -14.06% away from its average analyst target price of $49.45 per share.

Over the last year, HIMS's share price has increased by 199.5%, which represents a difference of 184.4% when compared to the S&P 500. The stock's 52 week high is $72.98 per share whereas its 52 week low is $13.47. With average free cash flows of $20.78 Million that have been growing at an average rate of 44.7% over the last 5 years, Hims & Hers Health is in a position to continue its strong stock performance trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2024 251,084 38,800 212,284 277.31
2023 73,483 17,220 56,263 292.39
2022 -26,531 2,714 -29,245 17.02
2021 -34,412 832 -35,244 -735.96
2020 -2,479 1,737 -4,216 94.39
2019 -74,867 308 -75,175
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS